A5065705574- Salivary Gland Disorders and Functions
- Salivary Gland Tumors Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Systemic Sclerosis and Related Diseases
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Oral Health Pathology and Treatment
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Ocular Surface and Contact Lens
- Diabetes and associated disorders
- Psoriasis: Treatment and Pathogenesis
- Galectins and Cancer Biology
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Atherosclerosis and Cardiovascular Diseases
- Lymphatic System and Diseases
- Chemokine receptors and signaling
- Growth Hormone and Insulin-like Growth Factors
- Bone and Joint Diseases
- Urticaria and Related Conditions
- Lymphoma Diagnosis and Treatment
- Dermatologic Treatments and Research
- Connective Tissue Growth Factor Research
- Autoimmune and Inflammatory Disorders Research
- Osteomyelitis and Bone Disorders Research
University of Groningen
2016-2025
University Medical Center Groningen
2016-2025
University Medical Center
2020-2024
Center for Rheumatology
2014-2022
Dialyse Centrum Groningen
2012-2021
University of Amsterdam
2017
John Wiley & Sons (United States)
2016
Hudson Institute
2016
Radboud University Medical Center
2014
Radboud University Nijmegen
2014
To develop a disease activity index for patients with primary Sjögren's syndrome (SS): the European League Against Rheumatism (EULAR) (ESSDAI).
Abstract Objective To investigate the safety and efficacy of B cell depletion treatment patients with active primary Sjögren's syndrome short duration (early SS) SS mucosa‐associated lymphoid tissue (MALT)–type lymphoma (MALT/primary SS). Methods Fifteen were included in this phase II trial. Inclusion criteria for early group hyperactivity (IgG >15 gm/liter), presence autoantibodies (IgM rheumatoid factor, anti‐SSA/SSB), disease (<4 years). MALT/primary an associated MALT‐type (Ann...
To develop a score for assessment of patients' symptoms in primary Sjögren's syndrome (SS): the EULAR SS Patient Reported Index (ESSPRI).Dryness, pain, somatic and mental fatigue were identified as main patients with SS, studies developing Profile Fatigue Discomfort (PROFAD) Sicca Symptoms Inventory (SSI). It was suspected that single 0-10 numerical scale each domain sufficient to assess these symptoms. These four scales gathered form ESSPRI. 230 patients, from 12 countries completed ESSPRI,...
Abstract Objective To study the efficacy and safety of B cell depletion with rituximab, a chimeric murine/human anti‐CD20 monoclonal antibody, in patients primary Sjögren's syndrome (SS) double‐blind, randomized, placebo‐controlled trial. Methods Patients active SS, as determined by revised American–European Consensus Group criteria, rate stimulated whole saliva secretion ≥0.15 ml/minute were treated either rituximab (1,000 mg) or placebo infusions on days 1 15. assigned randomly to...
The therapeutic management of Sjögren syndrome (SjS) has not changed substantially in recent decades: treatment decisions remain challenging clinical practice, without a specific target beyond the relief symptoms as most important goal. In view this scenario, European League Against Rheumatism (EULAR) promoted and supported an international collaborative study (EULAR SS Task Force) aimed at developing first EULAR evidence consensus-based recommendations for patients with SjS topical systemic...
To define disease activity levels, minimal clinically important improvement (MCII) and patient-acceptable symptom state (PASS) with the primary Sjögren's syndrome (SS) indexes: European League Against Rheumatism (EULAR) SS index (ESSDAI) EULAR patient-reported (ESSPRI).For 790 patients from two large prospective cohorts, ESSDAI, physician evaluation of activity, ESSPRI patients' satisfaction their current health status were recorded. Receiver operating characteristic curve analyses anchoring...
Labial salivary gland (LSG) biopsy is used in the classification of primary Sjögren's syndrome (PSS) and patient stratification clinical trials. It may also function as a biomarker. The acquisition tissue histological interpretation variable needs to be standardised for use A modified European League Against Rheumatism consensus guideline development strategy was used. steering committee ad hoc working group identified key outstanding points variability LSG analysis. 2-day workshop held...
<h3>Objectives</h3> To validate the two recently developed disease activity indexes for assessment of primary Sjögren9s syndrome (SS): European League Against Rheumatism (EULAR) SS Patient Reported Index (ESSPRI) and EULAR Disease Activity (ESSDAI). <h3>Methods</h3> A prospective international 6-month duration validation study was conducted in 15 countries. At each visit, physicians completed ESSDAI, index (SSDAI), Systemic Clinical (SCAI) physician global (PhGA); patients ESSPRI, Sicca...
<h3>Objective</h3> To assess the efficacy and safety of abatacept in patients with early active primary Sjögren9s syndrome (pSS). <h3>Methods</h3> All 15 (12 women, three men) included open-label Active Sjögren Abatacept Pilot study met revised American-European Consensus Group criteria for pSS were biological disease-modifying antirheumatic drug-naive. Patients treated eight intravenous infusions on days 1, 29 every 4 weeks thereafter. Follow-up was conducted at 4, 12, 24 (on treatment), 36...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but has been lacking. Previously, an international task force consisting representatives medical specialists published framework such definition, without reaching final recommendation. Methods Several systematic literature reviews were performed specific research questions examined suitably chosen data sets. The findings discussed, reformulated...
Alterations in the microbiota composition of gastro-intestinal tract are suspected to be involved etiopathogenesis two closely related systemic inflammatory autoimmune diseases: primary Sjögren's syndrome (pSS) and lupus erythematosus (SLE). Our objective was assess whether alterations gut oral compositions specific for pSS SLE.16S ribosomal RNA gene sequencing performed on fecal samples from 39 patients, 30 SLE patients 965 individuals general population, as well buccal swab washing same...
To compare health-related quality of life (HR-QOL), employment and disability primary secondary SS (pSS sSS, respectively) patients with the general Dutch population.HR-QOL, were assessed in regularly attending University Medical Center Groningen (n = 235). HR-QOL, evaluated Short Form-36 questionnaire (SF-36) an questionnaire. Results compared population data (matched for sex age). Demographical clinical associated assessed.Response rate was 83%. scored lower on HR-QOL than population. sSS...
Fc gamma receptors of class IIa (Fc RIIa) occur in 2 allelic forms, with either a low (IIa-R131) or high (IIa-H131) affinity for complexed IgG2 and IgG3. This polymorphism might have implications the handling immune complexes. Therefore, we determined distribution RIIa allotypes patients systemic lupus erythematosus (SLE), without history nephritis.We studied 95 unrelated white European SLE, as defined by American College Rheumatology criteria, 50 whom had nephritis, 69 healthy control...
To analyse the influence of geolocation and ethnicity on clinical presentation primary Sjögren's syndrome (SjS) at diagnosis.The Big Data Sjögren Project Consortium is an international, multicentre registry designed in 2014. By January 2016, 20 centres from five continents were participating. Multivariable logistic regression analyses performed.We included 7748 women (93%) 562 men (7%), with a mean age diagnosis SjS 53 years. Ethnicity data available for 7884 patients (95%): 6174 (78%)...
Objective To assess the effect of abatacept (CTLA‐4Ig), which limits T cell activation, on homeostasis CD4+ subsets and cell–dependent B hyperactivity in patients with primary Sjögren's syndrome (SS). Methods Fifteen SS treated were included. Circulating analyzed by flow cytometry at baseline, during treatment course, after was completed. effector Treg cells identified based expression CD45RA, CXCR3, CCR6, CCR4, CXCR5, programmed death 1, inducible costimulator (ICOS), FoxP3. Serum levels...